Key result
GIRK2 channel signaling is abnormally enhanced in Down syndrome models, where its suppression improves cognition, but downregulated in Alzheimer's disease models, promoting neuronal death.
Why the study?
The impact of KCNJ6, encoding GIRK2 subunits of inwardly rectifying potassium channels, was reviewed to understand its role in neuronal abnormalities and cognitive impairment in Down syndrome and Alzheimer's disease.
Modulation of GIRK2 channels represents a potential therapeutic strategy for cognitive impairment in Down syndrome and neuroprotection in Alzheimer's disease.
GIRK2 modulation merits targeted preclinical follow-up in cognitive disorders; leaves open human translation and therapeutic viability.
Cognitive impairment in Down syndrome (DS) results from the abnormal expression of hundreds of genes. However, the impact of KCNJ6, a gene located in the middle of the 'Down syndrome critical region' of chromosome 21, seems to stand out. KCNJ6 encodes GIRK2 (KIR3.2) subunits of G protein-gated inwardly rectifying potassium channels, which serve as effectors for GABAB, m2, 5HT1A, A1, and many other postsynaptic metabotropic receptors. GIRK2 subunits are heavily expressed in neocortex, cerebellum, and hippocampus. By controlling resting membrane potential and neuronal excitability, GIRK2 channels may thus affect both synaptic plasticity and stability of neural circuits in the brain regions important for learning and memory. Here, we discuss recent experimental data regarding the role of KCNJ6/GIRK2 in neuronal abnormalities and cognitive impairment in models of DS and Alzheimer's disease (AD). The results compellingly show that signaling through GIRK2 channels is abnormally enhanced in mouse genetic models of Down syndrome and that partial suppression of GIRK2 channels with pharmacological or genetic means can restore synaptic plasticity and improve impaired cognitive functions. On the other hand, signaling through GIRK2 channels is downregulated in AD models, such as models of early amyloidopathy. In these models, reduced GIRK2 channel signaling promotes neuronal hyperactivity, causing excitatory-inhibitory imbalance and neuronal death. Accordingly, activation of GABAB/GIRK2 signaling by GIRK channel activators or GABAB receptor agonists may reduce Aβ-induced hyperactivity and subsequent neuronal death, thereby exerting a neuroprotective effect in models of AD.
No takes yet. Share an insight, caveat, or question.
Alexander M. Kleschevnikov (2022) conducted a review in Down syndrome and Alzheimer's disease. GIRK2 channel signaling was evaluated. GIRK2 channel signaling is abnormally enhanced in Down syndrome models, where its suppression improves cognition, but downregulated in Alzheimer's disease models, promoting neuronal death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: